Leflunomide as part of the treatment for multidrug‐resistant cytomegalovirus disease after lung transplantation: case report and review of the literature

Treatment of cytomegalovirus (CMV) disease in transplant patients is challenging and, with antiviral resistance to first‐line drugs, it remains uncertain which treatment algorithm to follow. Some data suggest that leflunomide, a pyrimidine synthesis inhibitor, can be used to treat resistant CMV infe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Transplant infectious disease 2013-12, Vol.15 (6), p.E243-E249
Hauptverfasser:	Verkaik, N.J., Hoek, R.A.S., Bergeijk, H., Hal, P.Th.W., Schipper, M.E.I., Pas, S.D., Beersma, M.F.C., Boucher, C.A.B., Jedema, I., Falkenburg, F., Hoogsteden, H.C., Blink, B., Murk, J.L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Algorithms Antiviral Agents - therapeutic use CMV Cytomegalovirus Cytomegalovirus - drug effects Cytomegalovirus Infections - drug therapy Cytomegalovirus Infections - transmission Drug Resistance, Viral Drug Therapy, Combination Female foscarnet Foscarnet - therapeutic use ganciclovir Ganciclovir - therapeutic use Humans Immunoglobulins - therapeutic use Isoxazoles - therapeutic use leflunomide lung transplant Lung Transplantation - adverse effects Middle Aged multidrug resistant Viral Load
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!